1 completed, 1 unknown, 1 withdrawn. 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Tf-CRM107: new trials by email Literature Review of Tf-CRM107 trials Research Report on Tf-CRM107
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors TransMID - Glioblastoma | Phase 3 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 30 | 2004-07-01 | 2016-09-22 |
| Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme TransMID™ - Glioblastoma Multiforme | Phase 3 | Withdrawn | Xenova Biomedix | 323 | 2004-05-01 | 2009-01-07 |
| Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma transferrin-CRM107 - Brain and Central Nervous System Tumors | Phase 1 | Unknown | Xenova Biomedix | 2002-07-01 | 2018-05-15 |
Brain Neoplasms (2) · Glioblastoma (2) · Astrocytoma (1) · Central Nervous System Neoplasms (1)
Xenova Biomedix (2) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
United States (3) · Australia (1)